Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Intercept Pharmaceuticals, Inc. (ICPT) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Intercept Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1270073.
Total stock buying since 2014: $56,967,856.
Total stock sales since 2014: $941,992,580.
Total stock option exercises since 2014: $7,441,640.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2021 | 237,000 | $5,036,730 | 2,193 | $53,662 | 0 | $0 |
| 2020 | 0 | $0 | 6,291,496 | $370,845,750 | 0 | $0 |
| 2019 | 6,407 | $414,286 | 116,877 | $12,174,932 | 89,362 | $2,226,137 |
| 2018 | 798,045 | $51,074,880 | 1,569,444 | $164,779,277 | 57,425 | $613,786 |
| 2017 | 0 | $0 | 65,976 | $8,076,305 | 44,835 | $434,950 |
| 2016 | 0 | $0 | 56,747 | $8,693,631 | 61,626 | $600,726 |
| 2015 | 0 | $0 | 866,879 | $239,356,188 | 191,613 | $1,984,898 |
| 2014 | 2,800 | $441,960 | 477,468 | $138,012,835 | 163,199 | $1,581,143 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2021-03 | 237,000 | $5,036,730 | 0 | $0 | 0 | $0 |
| 2021-01 | 0 | $0 | 2,193 | $53,662 | 0 | $0 |
| 2020-12 | 0 | $0 | 1,763 | $57,791 | 0 | $0 |
| 2020-08 | 0 | $0 | 4,501,192 | $219,450,028 | 0 | $0 |
| 2020-05 | 0 | $0 | 1,786,734 | $151,157,694 | 0 | $0 |
| 2020-04 | 0 | $0 | 239 | $19,616 | 0 | $0 |
| 2020-02 | 0 | $0 | 113 | $9,901 | 0 | $0 |
| 2020-01 | 0 | $0 | 1,455 | $150,720 | 0 | $0 |
| 2019-12 | 0 | $0 | 2,568 | $317,362 | 1,383 | $60,445 |
| 2019-11 | 0 | $0 | 72,418 | $7,016,266 | 65,980 | $1,553,699 |
| 2019-10 | 0 | $0 | 653 | $48,685 | 0 | $0 |
| 2019-09 | 0 | $0 | 800 | $56,000 | 0 | $0 |
| 2019-08 | 5,207 | $314,086 | 0 | $0 | 0 | $0 |
| 2019-07 | 0 | $0 | 595 | $46,802 | 0 | $0 |
| 2019-05 | 1,200 | $100,200 | 2,000 | $172,560 | 8,749 | $167,741 |
| 2019-04 | 0 | $0 | 3,156 | $322,950 | 7,250 | $252,852 |
| 2019-03 | 0 | $0 | 4,504 | $473,943 | 2,000 | $63,800 |
| 2019-02 | 0 | $0 | 25,438 | $3,241,365 | 2,000 | $63,800 |
| 2019-01 | 0 | $0 | 4,745 | $478,999 | 2,000 | $63,800 |
| 2018-12 | 0 | $0 | 7,000 | $773,847 | 2,000 | $63,800 |
| 2018-11 | 0 | $0 | 1,553,343 | $163,020,953 | 52,000 | $476,349 |
| 2018-10 | 0 | $0 | 4,184 | $436,586 | 3,425 | $73,637 |
| 2018-09 | 0 | $0 | 4,917 | $547,891 | 0 | $0 |
| 2018-04 | 798,045 | $51,074,880 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-03-12 | Akkaraju Srinivas | Buy | 147,000 | 21.29 | 3,129,630 |
| 2021-03-10 | Akkaraju Srinivas | Buy | 90,000 | 21.19 | 1,907,100 |
| 2021-01-05 | Kapadia Sandip (CFO and Treasurer) | Sale | 2,193 | 24.47 | 53,662 |
| 2020-12-15 | Kapadia Sandip (CFO and Treasurer) | Sale | 1,763 | 32.78 | 57,791 |
| 2020-08-18 | Campagna Jason (Chief Medical Officer) | Sale | 1,192 | 47.44 | 56,542 |
| 2020-08-17 | Micheli Francesco | Sale | 1,362,400 | 48.45 | 66,005,555 |
| 2020-08-17 | Fundaro Paolo | Sale | 1,362,400 | 48.45 | 66,005,555 |
| 2020-08-17 | Genextra S.p.a. | Sale | 1,362,400 | 48.45 | 66,005,555 |
| 2020-08-14 | Micheli Francesco | Sale | 54,600 | 50.55 | 2,760,139 |
| 2020-08-14 | Fundaro Paolo | Sale | 54,600 | 50.55 | 2,760,139 |
| 2020-08-14 | Genextra S.p.a. | Sale | 54,600 | 50.55 | 2,760,139 |
| 2020-08-13 | Micheli Francesco | Sale | 83,000 | 52.60 | 4,365,468 |
| 2020-08-13 | Fundaro Paolo | Sale | 83,000 | 52.60 | 4,365,468 |
| 2020-08-13 | Genextra S.p.a. | Sale | 83,000 | 52.60 | 4,365,468 |
| 2020-05-13 | Micheli Francesco (10% Owner) | Sale | 595,578 | 84.60 | 50,385,898 |
| 2020-05-13 | Fundaro Paolo (Director) | Sale | 595,578 | 84.60 | 50,385,898 |
| 2020-05-13 | Genextra S.p.a. (10% Owner) | Sale | 595,578 | 84.60 | 50,385,898 |
| 2020-04-27 | Weyer Christian (EVP, Research & Development) | Sale | 181 | 85.95 | 15,556 |
| 2020-04-09 | Ford David A (Chief Human Resources Officer) | Sale | 58 | 70.00 | 4,060 |
| 2020-02-27 | Weyer Christian (EVP, Research & Development) | Sale | 113 | 87.62 | 9,901 |
| 2020-01-27 | Weyer Christian (EVP, Research & Development) | Sale | 723 | 94.04 | 67,990 |
| 2020-01-07 | Campagna Jason (Chief Medical Officer) | Sale | 732 | 113.02 | 82,730 |
| 2019-12-31 | Cawkwell Gail (SVP, Med Affairs, Safety & PV) | Sale | 262 | 125.00 | 32,750 |
| 2019-12-31 | Cawkwell Gail (SVP, Med Affairs, Safety & PV) | Option Ex | 262 | 54.63 | 14,313 |
| 2019-12-31 | Pruzanski Mark (President & CEO) | Sale | 100 | 125.00 | 12,500 |
| 2019-12-31 | Pruzanski Mark (President & CEO) | Option Ex | 100 | 21.50 | 2,150 |
| 2019-12-27 | Weyer Christian (EVP, Research & Development) | Sale | 1,581 | 123.24 | 194,842 |
| 2019-12-27 | Weyer Christian (EVP, Research & Development) | Option Ex | 470 | 58.93 | 27,697 |
| 2019-12-26 | Cawkwell Gail (SVP, Med Affairs, Safety & PV) | Sale | 54 | 125.00 | 6,750 |
| 2019-12-26 | Cawkwell Gail (SVP, Med Affairs, Safety & PV) | Option Ex | 54 | 54.63 | 2,950 |
| 2019-12-26 | Pruzanski Mark (President & CEO) | Sale | 417 | 125.00 | 52,125 |
| 2019-12-26 | Pruzanski Mark (President & CEO) | Option Ex | 417 | 21.50 | 8,965 |
| 2019-12-19 | Campagna Jason (Chief Medical Officer) | Sale | 154 | 119.45 | 18,395 |
| 2019-12-03 | Cawkwell Gail (SVP, Med Affairs, Safety & PV) | Option Ex | 80 | 54.63 | 4,370 |
| 2019-11-27 | Weyer Christian (EVP, Research & Development) | Sale | 1,040 | 101.65 | 105,716 |
| 2019-11-27 | Weyer Christian (EVP, Research & Development) | Option Ex | 927 | 58.93 | 54,628 |
| 2019-11-26 | Pruzanski Mark (President & CEO) | Sale | 35,437 | 100.00 | 3,543,700 |
| 2019-11-26 | Pruzanski Mark (President & CEO) | Option Ex | 35,437 | 15.08 | 534,496 |
| 2019-11-26 | Weyer Christian (EVP, Research & Development) | Sale | 4,373 | 100.00 | 437,300 |
| 2019-11-26 | Weyer Christian (EVP, Research & Development) | Option Ex | 4,373 | 58.93 | 257,700 |
| 2019-11-25 | Pruzanski Mark (President & CEO) | Sale | 14,563 | 100.00 | 1,456,300 |
| 2019-11-25 | Pruzanski Mark (President & CEO) | Option Ex | 14,563 | 8.67 | 126,217 |
| 2019-11-25 | Weyer Christian (EVP, Research & Development) | Sale | 1,855 | 100.00 | 185,500 |
| 2019-11-25 | Weyer Christian (EVP, Research & Development) | Option Ex | 1,855 | 58.93 | 109,315 |
| 2019-11-19 | Sullivan Ryan T (General Counsel and Secretary) | Sale | 12,154 | 85.00 | 1,033,090 |
| 2019-11-19 | Sullivan Ryan T (General Counsel and Secretary) | Option Ex | 8,325 | 53.41 | 444,638 |
| 2019-11-19 | Weyer Christian (EVP, Research & Development) | Sale | 1,550 | 85.00 | 131,750 |
| 2019-11-13 | Sullivan Ryan T (General Counsel and Secretary) | Sale | 500 | 85.00 | 42,500 |
| 2019-11-13 | Sullivan Ryan T (General Counsel and Secretary) | Option Ex | 500 | 53.41 | 26,705 |
| 2019-11-13 | Weyer Christian (EVP, Research & Development) | Sale | 946 | 85.00 | 80,410 |
| 2019-10-29 | Bright Lisa (President, International) | Sale | 595 | 75.00 | 44,625 |
| 2019-10-23 | Ford David A (Chief Human Resources Officer) | Sale | 58 | 70.00 | 4,060 |
| 2019-09-16 | Ford David A (Chief Human Resources Officer) | Sale | 800 | 70.00 | 56,000 |
| 2019-08-28 | Akkaraju Srinivas (Director) | Buy | 5,207 | 60.32 | 314,086 |
| 2019-07-03 | Bright Lisa (President, International) | Sale | 595 | 78.66 | 46,802 |
| 2019-05-20 | Fundaro Paolo | Option Ex | 6,749 | 15.40 | 103,941 |
| 2019-05-14 | Benatti Luca | Buy | 1,200 | 83.50 | 100,200 |
| 2019-05-01 | Shapiro David (Chief Medical Officer) | Sale | 2,000 | 86.28 | 172,560 |
| 2019-05-01 | Shapiro David (Chief Medical Officer) | Option Ex | 2,000 | 31.90 | 63,800 |
| 2019-04-25 | Akkaraju Srinivas | Option Ex | 3,500 | 26.70 | 93,450 |
| 2019-04-18 | Cawkwell Gail (SVP, Med Affairs, Safety & PV) | Option Ex | 1,750 | 54.63 | 95,602 |
| 2019-04-15 | Shapiro David (Chief Medical Officer) | Sale | 2,000 | 95.00 | 190,000 |
| 2019-04-15 | Shapiro David (Chief Medical Officer) | Option Ex | 2,000 | 31.90 | 63,800 |
| 2019-04-03 | Bright Lisa (President, International) | Sale | 594 | 115.01 | 68,315 |
| 2019-04-03 | Shapiro David (Chief Medical Officer) | Sale | 562 | 115.01 | 64,635 |
| 2019-03-29 | Fundaro Paolo | Sale | 2,171 | 107.45 | 233,271 |
| 2019-03-01 | Shapiro David (Chief Medical Officer) | Sale | 2,000 | 103.16 | 206,320 |
| 2019-03-01 | Shapiro David (Chief Medical Officer) | Option Ex | 2,000 | 31.90 | 63,800 |
| 2019-03-01 | Weyer Christian (EVP, Research & Development) | Sale | 333 | 103.16 | 34,352 |
| 2019-02-19 | Akkaraju Srinivas (Director) | Sale | 23,438 | 128.78 | 3,018,345 |
| 2019-02-15 | Shapiro David (Chief Medical Officer) | Sale | 2,000 | 111.51 | 223,020 |
| 2019-02-15 | Shapiro David (Chief Medical Officer) | Option Ex | 2,000 | 31.90 | 63,800 |
| 2019-01-07 | Bright Lisa (President, International) | Sale | 1,313 | 104.93 | 137,773 |
| 2019-01-04 | Shapiro David (Chief Medical Officer) | Sale | 474 | 97.48 | 46,205 |
| 2019-01-03 | Ford David A (Chief Human Resources Officer) | Sale | 259 | 117.16 | 30,344 |
| 2019-01-03 | Shapiro David (Chief Medical Officer) | Sale | 699 | 97.45 | 68,117 |
| 2019-01-02 | Shapiro David (Chief Medical Officer) | Sale | 2,000 | 98.28 | 196,560 |
| 2019-01-02 | Shapiro David (Chief Medical Officer) | Option Ex | 2,000 | 31.90 | 63,800 |
| 2018-12-17 | Shapiro David (Chief Medical Officer) | Sale | 2,000 | 106.62 | 213,240 |
| 2018-12-17 | Shapiro David (Chief Medical Officer) | Option Ex | 2,000 | 31.90 | 63,800 |
| 2018-12-04 | Bright Lisa (President, International) | Sale | 300 | 111.00 | 33,300 |
| 2018-12-03 | Bright Lisa (President, International) | Sale | 4,700 | 112.19 | 527,307 |
| 2018-11-29 | Micheli Francesco | Sale | 750,000 | 105.07 | 78,802,500 |
| 2018-11-29 | Genextra S.p.a. | Sale | 750,000 | 105.07 | 78,802,500 |
| 2018-11-29 | Weyer Christian (EVP, Research & Development) | Sale | 1,343 | 113.78 | 152,806 |
| 2018-11-16 | Pruzanski Mark (President & CEO) | Sale | 27,606 | 101.94 | 2,814,155 |
| 2018-11-16 | Pruzanski Mark (President & CEO) | Option Ex | 27,606 | 8.67 | 239,261 |
| 2018-11-15 | Pruzanski Mark (President & CEO) | Sale | 22,394 | 100.76 | 2,256,352 |
| 2018-11-15 | Pruzanski Mark (President & CEO) | Option Ex | 22,394 | 8.67 | 194,088 |
| 2018-11-01 | Shapiro David (Chief Medical Officer) | Sale | 2,000 | 96.32 | 192,640 |
| 2018-11-01 | Shapiro David (Chief Medical Officer) | Option Ex | 2,000 | 21.50 | 43,000 |
| 2018-10-15 | Shapiro David (Chief Medical Officer) | Sale | 3,425 | 102.95 | 352,603 |
| 2018-10-15 | Shapiro David (Chief Medical Officer) | Option Ex | 3,425 | 21.50 | 73,637 |
| 2018-10-05 | Shapiro David (Chief Medical Officer) | Sale | 759 | 110.65 | 83,983 |
| 2018-09-05 | Shapiro David (Chief Medical Officer) | Sale | 4,917 | 111.43 | 547,891 |
| 2018-04-09 | Gottesdiener Keith Michael | Buy | 1,171 | 64.00 | 74,944 |
| 2018-04-09 | Micheli Francesco | Buy | 390,625 | 64.00 | 25,000,000 |
| 2018-04-09 | Pruzanski Mark (CEO & President) | Buy | 7,812 | 64.00 | 499,968 |
| 2018-04-09 | Genextra S.p.a. | Buy | 390,625 | 64.00 | 25,000,000 |
| 2018-04-09 | Bradbury Daniel | Buy | 7,812 | 64.00 | 499,968 |
| 2017-10-02 | Kim Richard J (SVP, Commercial US) | Sale | 48 | 58.10 | 2,788 |
| 2017-10-02 | Kapadia Sandip (Chief Financial Officer) | Sale | 354 | 58.83 | 20,826 |
| 2017-10-02 | Bright Lisa (President International) | Sale | 390 | 58.92 | 22,979 |
| 2017-10-02 | Mcminn Rachel (Chief Strategy Officer) | Sale | 283 | 58.89 | 16,666 |
| 2017-10-02 | Shapiro David (CMO and EVP - Development) | Sale | 349 | 58.90 | 20,555 |
| 2017-10-02 | Pruzanski Mark (CEO & President) | Sale | 1,532 | 58.87 | 90,188 |
| 2017-09-01 | Shapiro David (CMO and EVP - Development) | Sale | 1,250 | 117.43 | 146,787 |
| 2017-09-01 | Shapiro David (CMO and EVP - Development) | Option Ex | 1,250 | 31.90 | 39,875 |
| 2017-08-25 | Bright Lisa (President International) | Sale | 253 | 111.32 | 28,163 |
| 2017-08-02 | Bright Lisa (President International) | Sale | 142 | 110.29 | 15,660 |
| 2017-08-01 | Shapiro David (CMO and EVP - Development) | Sale | 1,118 | 119.00 | 133,042 |
| 2017-08-01 | Shapiro David (CMO and EVP - Development) | Option Ex | 1,118 | 8.67 | 9,689 |
| 2017-07-31 | Mcminn Rachel (Chief Strategy Officer) | Sale | 130 | 123.12 | 16,005 |
| 2017-07-31 | Welch Daniel G | Sale | 602 | 123.93 | 74,603 |
| 2017-07-20 | Welch Daniel G | Sale | 217 | 126.76 | 27,506 |
| 2017-07-14 | Kim Richard J (SVP, Commercial US) | Sale | 89 | 128.64 | 11,449 |
| 2017-07-11 | Shapiro David (CMO and EVP - Development) | Sale | 553 | 124.01 | 68,577 |
| 2017-07-03 | Kim Richard J (SVP, Commercial US) | Sale | 50 | 121.69 | 6,084 |
| 2017-07-03 | Kapadia Sandip (Chief Financial Officer) | Sale | 1,431 | 121.59 | 173,999 |
| 2017-07-03 | Bright Lisa (President International) | Sale | 394 | 121.33 | 47,802 |
| 2017-07-03 | Mcminn Rachel (Chief Strategy Officer) | Sale | 257 | 121.78 | 31,297 |
| 2017-07-03 | Shapiro David (CMO and EVP - Development) | Sale | 350 | 121.28 | 42,446 |
| 2017-07-03 | Pruzanski Mark (CEO & President) | Sale | 1,434 | 121.78 | 174,632 |
| 2017-06-26 | Pruzanski Mark (CEO & President) | Sale | 40,000 | 131.35 | 5,254,000 |
| 2017-06-26 | Pruzanski Mark (CEO & President) | Option Ex | 40,000 | 8.67 | 346,680 |
| 2017-06-01 | Bright Lisa (President International) | Sale | 698 | 110.74 | 77,297 |
| 2017-05-25 | Bright Lisa (President International) | Sale | 254 | 117.52 | 29,850 |
| 2017-05-16 | Bright Lisa (President International) | Sale | 113 | 119.66 | 13,521 |
| 2017-05-02 | Bright Lisa (President International) | Sale | 426 | 114.00 | 48,564 |
| 2017-05-01 | Mcminn Rachel (Chief Strategy Officer) | Sale | 114 | 113.12 | 12,895 |
| 2017-05-01 | Shapiro David (CMO and EVP - Development) | Sale | 1,117 | 112.18 | 125,305 |
| 2017-05-01 | Shapiro David (CMO and EVP - Development) | Option Ex | 1,117 | 8.67 | 9,681 |
| 2017-04-10 | Shapiro David (CMO and EVP - Development) | Sale | 558 | 108.51 | 60,548 |
| 2017-04-03 | Bright Lisa (President International) | Sale | 389 | 115.00 | 44,733 |
| 2017-04-03 | Mcminn Rachel (Chief Strategy Officer) | Sale | 257 | 115.00 | 29,554 |
| 2017-04-03 | Shapiro David (CMO and EVP - Development) | Sale | 346 | 115.00 | 39,788 |
| 2017-04-03 | Pruzanski Mark (CEO & President) | Sale | 1 | 115.00 | 114 |
| 2017-03-02 | Bright Lisa (President International) | Sale | 1,313 | 130.16 | 170,904 |
| 2017-03-01 | Bright Lisa (President International) | Sale | 136 | 130.16 | 17,701 |
| 2017-03-01 | Shapiro David (CMO and EVP - Development) | Sale | 1,350 | 128.66 | 173,691 |
| 2017-03-01 | Shapiro David (CMO and EVP - Development) | Option Ex | 1,350 | 21.50 | 29,025 |
| 2017-02-27 | Bright Lisa (President International) | Sale | 254 | 119.48 | 30,347 |
| 2017-01-31 | Bright Lisa (President International) | Sale | 134 | 108.96 | 14,600 |
| 2017-01-09 | Shapiro David (CMO and EVP - Development) | Sale | 1,565 | 106.01 | 165,905 |
| 2017-01-03 | Bright Lisa (President International) | Sale | 1,119 | 103.92 | 116,285 |
| 2017-01-03 | Mcminn Rachel (Chief Strategy Officer) | Sale | 816 | 103.92 | 84,797 |
| 2017-01-03 | Shapiro David (CMO and EVP - Development) | Sale | 988 | 103.92 | 102,671 |
| 2017-01-03 | Pruzanski Mark (CEO & President) | Sale | 2,802 | 103.92 | 291,181 |
| 2016-12-06 | Pruzanski Mark (CEO & President) | Option Ex | 3,487 | 26.70 | 93,102 |
| 2016-12-02 | Shapiro David (CMO and EVP - Development) | Sale | 4,050 | 99.75 | 403,986 |
Insider trading activities including stock purchases, stock sales, and option exercises of ICPT listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Intercept Pharmaceuticals, Inc. (symbol ICPT, CIK number 1270073) see the Securities and Exchange Commission (SEC) website.